Interpace Diagnostics to Present New Data in Six Posters Related to PancraGEN™ at Upcoming Annual DDW International Meeting on May 6-9, 2017

PARSIPPANY, N.J., May 1, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company" or "Interpace Diagnostics"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today the acceptance of 6 abstracts that will be presented as posters at the upcoming Digestive Disease Week (DDW) meeting being held May 6th-9th, 2017 in Chicago, Illinois. Three abstracts address the utility of PancraGEN™ in assessing long-term risk of malignancy in pancreatic cystic lesions and clinical scenarios in which such testing is most impactful. The conclusions are supported by data based on real-world clinical practice and patient outcomes and include 370 patients who underwent multiple PancraGEN tests over the course of 3 years. Three additional posters describe the expanded use of PancraGEN as an ancillary test for solid lesions of the pancreas and bile duct using the company's unique method for testing free-DNA obtained from bile duct brushings and fine needle aspirates. Notably, the abstracts describe results from a registry study of over 200 patients and a prospective study of 100 patients who received such testing.

The accepted posters that will be presented at the conference are entitled:

- "DNA Analysis of Pancreatic Cystic Fluid has Incremental Predictive Value in Assessing Future Risk of Malignant Outcomes"
- "Carcinoembryonic Antigen (CEA) Level in Cyst Fluid of Pancreatic Cyst has Poor Test Reliability and Should not be Used in Categorizing Incidental Pancreatic Cystic Lesions"
- "Being More Confidently Conservative: Mutational Profiling of Non-diagnostic Cytology Samples in Patients with Solid Pancreato-biliary Lesion (SPL) Impacts Clinical Decision Making"
- "PCR Based Mutation Profiling of Free DNA Enhances Cytology and FISH Based Detection of Malignancy in Patients with Biliary Structures Undergoing ERCP: A Prospective Study"
- "Prospective Molecular Mutational Analysis of Stent Supernatant in the Characterization of Benign and Malignant Biliary Strictures, an Interim Analysis"
- "High variability in serial pancreatic cyst fluid characteristics suggests that longer intervals of surveillance may be warranted"

According to Syd Finkelstein, Chief Medical & Scientific Officer of Interpace, "We are pleased that this work has been accepted for presentation at the upcoming DDW meeting. The acceptance of these six posters by this prestigious organization reflects the strength of our ongoing commitment to demonstrate the exceptional clinical utility of PancraGEN. We are hopeful that these studies and analyses will be supportive of expanding the current Guidelines to further support the use of molecular diagnostics in pancreatic cancer diagnosis."

About DDW

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW take place May 6-9, 2017, at McCormick Place, Chicago, IL. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

About PancraGEN®

PancraGEN® is a pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate, according to clinical studies, enabling effective risk stratification of patients. Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of
cancer deaths.

**About Interpace Diagnostics Group, Inc.**

Interpace has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace’s mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics’ website at [www.interpacediagnostics.com](http://www.interpacediagnostics.com)

**Forward Looking Statements**

*This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company’s ability to adequately finance the business, its ability to restructure its liabilities and other obligations, the market’s acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability to maintain its NASDAQ listing. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company’s filings with the SEC, including without limitation, the Annual Report on Form 10-K relating to our year ended December 31, 2016 filed with the SEC on March 31, 2017. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

**CONTACTS:**

Interpace Diagnostics
Investor Relations:
Paul Kuntz, RedChip
Paul@Redchip.com


**SOURCE** Interpace Diagnostics Group, Inc.